Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transient BRAF/MEK Inhibition + Pembrolizumab in Resistant Melanoma
NCT05304546Phase 2Completed
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in melanoma. Primary endpoints: Decrease in nuclear c-MYC levels in situ at 48 months, Increase in mitochondrial proteins ACAT1 and HADHA at 48 months and 2 more. Started Sep 2023; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05304546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304546.